Ads
related to: new drugs for pulmonary hypertension- PAH Signs and Symptoms
Find Info on Common Symptoms
That Are Attributable to PAH.
- Risk Assessment
Visit Site to View Guidelines
For PAH Risk Assessment.
- Dosing & Administration
View Full Prescribing and
Safety Information.
- Primary Endpoint
Review the Primary Endpoint
in a Clinical Trial of a PAH Drug.
- Video Library
Professional & Patient Perspectives
of Potential Treatment Option.
- Clinical Trial Info
Visit Site to View Clinical Trial
and Safety Information.
- PAH Signs and Symptoms
Search results
Results From The WOW.Com Content Network
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). [3] [4] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. [5]
Ambrisentan is a drug that blocks endothelin, an endogenous hormone found in higher quantities in patients with pulmonary arterial hypertension. Endothelin binds to two receptors, ET A and ET B . ET A is responsible for cell growth in the vessels as well as vasoconstriction , while ET B plays a role in vasodilation , endothelin 1 clearance, and ...
Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure in the arteries of the lungs. [7] Symptoms include shortness of breath, fainting, tiredness, chest pain, swelling of the legs, and a fast heartbeat. [7] [1] The condition may make it difficult to exercise. [7] Onset is typically gradual. [8]
Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). [1] It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity. [2]
Soluble guanylate cyclase (sGC) stimulators are a class of drugs developed to treat heart failure, pulmonary hypertension, and other diseases. The first-in-class medication was riociguat, approved in 2013 for pulmonary hypertension. [1] [2] They have also been investigated for hypertension, systemic sclerosis, and sickle cell disease. [3] [1]
Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. [6] It is an activin signaling inhibitor, [6] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). [9]
Ads
related to: new drugs for pulmonary hypertension